Key results from the ROCKET AF renal impairment subanalysis (19) | Download Table
Recent Advances in Oral Anticoagulation Therapy for Patients with Atrial Fibrillation
Prevention of Thromboembolism in Atrial Fibrillation: Factor XA and Thrombin Inhibitors | Basicmedical Key
Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Meta-analysis of large NOAC trials shows favourable risk/benefit ratio over warfarin - PACE-CME
Stroke Prevention in AF – A new Paradigm - ppt download
Efficacy of rivaroxaban to prevent stroke in atrial fibriallation maintained in elderly - PACE-CME
Xarelto® (rivaroxaban) – ROCKET AF
RE-LY, ROCKET AF, and ARISTOTLE trial design and conduct. | Download Table
60371-5.fp.png "OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL | Journal of the American College of Cardiology")
OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL | Journal of the American College of Cardiology
Use of NOAC drugs in DC cardioversion for patients with non-valvular AF - The British Journal of Cardiology
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | NEJM
Cureus | Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation | Journal of the American Heart Association
Safety Profile - NVAF | XARELTO® (rivaroxaban) HCP
Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan - Journal of Stroke and Cerebrovascular Diseases
CLINICAL REVIEW - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation - NCBI Bookshelf
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation | NEJM
ROCKET AF Results - Duke Clinical Research Institute
Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation | Open Heart
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial) - American Journal of Cardiology
